• Causal Roles of CLEC5A and ISG20 in Atherosclerosis Progress

  2026-05-11

  Zhang et al. integrate Mendelian randomization and eQTL analyses to establish CLEC5A and ISG20 as causal drivers of atherosclerosis, linking these genes to immune and inflammatory mechanisms. Their work provides new mechanistic insight into atherogenesis, highlighting ISG20 as a potential therapeutic target and underscoring the value of rigorous experimental validation.

• CBD Attenuates Orofacial Inflammatory Pain via Endocannabino

  2026-05-11

  This study demonstrates that cannabidiol (CBD) significantly reduces both the sensory and affective dimensions of orofacial inflammatory pain in mouse models. By dissecting peripheral and central mechanisms, the research provides mechanistic insights into endocannabinoid system modulation relevant for future cannabinoid receptor research and multidimensional pain management.

• Influenza Hemagglutinin (HA) Peptide: Optimizing Immunopreci

  2026-05-10

  The Influenza Hemagglutinin (HA) Peptide empowers researchers with reproducible, high-purity solutions for precise detection and efficient elution of HA-tagged fusion proteins. Discover stepwise protocol enhancements, troubleshooting strategies, and advanced applications that set APExBIO's HA tag peptide apart in molecular workflows.

• BML-277 and the Nuclear cGAS-CHK2 Axis: Next-Gen Radioprotec

  2026-05-09

  Explore how BML-277, a potent Chk2 inhibitor, uniquely enables targeted manipulation of the nuclear cGAS-CHK2-TRIM41 pathway for DNA damage response and T-cell radioprotection. This article delivers advanced insights and protocol guidance distinct from standard product overviews.

• T0070907: A Precision PPARγ Antagonist for Advanced Cell Ass

  2026-05-09

  T0070907 is a nanomolar PPARγ antagonist that enables high-affinity, selective pathway inhibition for dissecting adipogenesis, cancer cell cycle arrest, and inflammation signaling. Applied in workflows from 3T3-L1 adipogenesis to cancer radiosensitivity, its robust performance streamlines both routine and advanced mechanistic research.

• Ribociclib succinate (SKU B1084): Reliable CDK Inhibitor Wor

  2026-05-08

  This article provides evidence-based guidance on leveraging Ribociclib succinate (SKU B1084) in cell cycle and cytotoxicity assays. Through scenario-driven Q&A, it addresses solubility, assay compatibility, protocol optimization, and vendor selection, helping life science researchers improve reproducibility and interpretability in cancer research workflows.

• All-trans Retinoic Acid Reverses Cisplatin-Induced PARPi Res

  2026-05-07

  This study reveals that all-trans retinoic acid (ATRA) can restore sensitivity to PARP inhibition in epithelial ovarian cancer (EOC) cells that have developed resistance following cisplatin treatment. By elucidating the molecular mechanisms of resistance and demonstrating a clinically feasible combination strategy, the research advances maintenance therapy options for BRCA-mutant and platinum-treated ovarian cancers.

• Mifepristone (RU486): Protocols for Cancer and Fertility Res

  2026-05-07

  Mifepristone (RU486) unlocks targeted control of progesterone receptor signaling for applications from cancer cell inhibition to reproductive biology. Explore data-backed workflows, troubleshooting strategies, and real-world protocol upgrades to maximize reproducibility and insight.

• Naftifine HCl: Enhancing Antifungal Research & Protocol Prec

  2026-05-06

  Naftifine HCl, a potent allylamine antifungal agent from APExBIO, empowers researchers to dissect sterol biosynthesis and optimize topical antifungal workflows. This article presents actionable protocols, advanced applications, and troubleshooting guidance tailored for mycology and cell signaling studies, translating cutting-edge reference insights into practical experimental strategies.

• LNP-NamiRNA Targeting of Pancreatic Cancer: Dual Suppression

  2026-05-06

  Yu et al. (2025) reveal that lipid nanoparticle (LNP)-delivered miR-200c, a nuclear activating miRNA (NamiRNA), inhibits pancreatic cancer progression through two distinct mechanisms: transcriptional activation of PTPN6 via enhancer engagement and post-transcriptional repression of CDH17. This dual action provides new mechanistic insight into miRNA regulation in cancer and suggests a promising therapeutic avenue.

• Cyclic Pifithrin-α Hydrobromide: Optimizing p53 Inhibition W

  2026-05-05

  Cyclic Pifithrin-α hydrobromide enables precise, selective inhibition of p53 for dissecting apoptosis, DNA damage responses, and protection from irradiation. This guide translates recent neuroinflammatory insights and comparative protocol strategies into actionable workflows and troubleshooting tips for researchers seeking high-fidelity p53 pathway modulation.

• CCK Interneurons in the Amygdala Modulate Stress-Induced Anx

  2026-05-05

  This study demonstrates that chemogenetic and optogenetic activation of cholecystokinin-expressing interneurons (CCK-INs) in the basolateral amygdala (BLA) effectively suppresses stress-induced anxiety-like behaviors in mice. The findings highlight the pivotal role of CCK-IN-mediated inhibitory transmission and plasticity in regulating neuronal activity relevant to anxiety, offering new mechanistic insight for neuroscience research.

• Amikacin Sulfate: Precision Delivery for Mycobacterial Resea

  2026-05-04

  This thought-leadership article explores the evolving role of Amikacin Sulfate in translational mycobacterial research, emphasizing mechanistic insight into intracellular targeting, experimental validation of dendritic cell-mediated delivery, and strategic guidance for researchers seeking to maximize efficacy while minimizing toxicity. Drawing on landmark studies and APExBIO’s rigorously validated product, this piece offers actionable intelligence for investigators charting the next generation of targeted antibiotic interventions.

• Anti Reverse Cap Analog: Optimizing Synthetic mRNA Capping

  2026-05-04

  Harnessing Anti Reverse Cap Analog (ARCA), 3´-O-Me-m7G(5')ppp(5')G, researchers can achieve superior translational efficiency and capping specificity in synthetic mRNA workflows. This article provides data-driven protocol enhancements, troubleshooting strategies, and a unique integration of recent mitochondrial protein regulation findings for mRNA therapeutics and metabolic studies.

• γH2AX DNA Damage Detection: Frontier Insights for Translatio

  2026-05-03

  This article guides translational researchers through the mechanistic foundations and strategic value of γH2AX DNA Damage Detection, contextualized by recent breakthroughs in radioimmunotherapy and immune-oncology. Integrating evidence from leading-edge studies and benchmarking APExBIO’s γH2AX DNA Damage Detection Kit, it offers actionable recommendations for DNA damage and repair research, apoptosis assays, and genotoxicity assessment—while also highlighting new experimental and clinical frontiers.

16279 records 1/1086 page Next 12345 下5页 Last page